The MarketWatch News Department was not involved in the creation of this content. The First Synaptic Regenerative Drug, SPG302, Led to Slowed Disease Progression in ALS Patients LOS ANGELES, Nov. 4, ...
Introduction to the nature and possible meanings of higher education, and the functions and resources of the University. Designed to help students develop and exercise fundamental academic success ...
VectorY Therapeutics Receives FDA Clearance of IND to Proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002, a First-in-Class Vectorized Antibody Targeting TDP-43 Pathology in ALS VectorY ...
LOS ANGELES, Nov. 4, 2025 /PRNewswire/ -- Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics designed to restore synapses to improve health in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback